Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an announcement.
NIOX Group plc announced an update on its total voting rights, revealing that the company’s issued share capital consists of 417,879,117 Ordinary Shares, each with one voting right. This follows the exercise of options by employees over 7,500 Ordinary Shares under the company’s share option schemes. The new shares have been admitted via block listing and rank equally with existing shares. This update is crucial for shareholders as it affects their calculations for notifying interest changes under FCA rules.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £76.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and cash flow management. The technical analysis indicates a positive trend, though momentum is limited. The high P/E ratio suggests potential overvaluation, partially offset by a decent dividend yield.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc operates in the pharmaceutical industry, focusing on the development and commercialization of products that aid in respiratory diagnostics and management. The company is known for its innovative solutions in the healthcare sector, particularly targeting respiratory diseases.
Average Trading Volume: 803,289
Technical Sentiment Signal: Buy
Current Market Cap: £289.2M
Learn more about NIOX stock on TipRanks’ Stock Analysis page.